| Literature DB >> 24069205 |
Tomoko Oeda1, Atsushi Umemura, Satoshi Tomita, Ryutaro Hayashi, Masayuki Kohsaka, Hideyuki Sawada.
Abstract
BACKGROUND: Abnormal posture (AP) is often seen in Parkinson's disease (PD), and marked forms known as dropped head syndrome and camptocormia encumber daily living activities. Unlike other motor disabilities such as bradykinesia or muscular rigidity, AP is not always improved but rather deteriorated by PD medication.Entities:
Mesh:
Year: 2013 PMID: 24069205 PMCID: PMC3777935 DOI: 10.1371/journal.pone.0073547
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Surveyed posture angles in healthy controls (n = 175) and patients with PD (n = 216).
NF angle and FB angle were distributed in a bell shape. They were shifted rightward in PD patients compared with healthy controls.
Demographic data by quartiles of neck-flexion angle.
| 1st quartile | 2nd quartile | 3rd quartile | 4th quartile | |||||||||||||||
| n = 60 | n = 50 | n = 50 | n = 56 | |||||||||||||||
| (0.1–4.9) | (5.1–9.9) | (10.2–16.9) | (17.2–83.2) |
| ||||||||||||||
| Age (Y), mean (SEM) | 69.4 | ( | 1.1 | ) | 68.1 | ( | 1.4 | ) | 67.8 | ( | 1.3 | ) | 70.3 | ( | 1.1 | ) | 0.45 | |
| Sex, n (%) | Female Male | 40 20 | ( ( | 66.7% 33.3% | ) ) | 25 25 | ( ( | 50.0% 50.0% | ) ) | 32 18 | ( ( | 64.0% 36.0% | ) ) | 36 20 | ( ( | 64.3% 35.7% | ) ) | 0.285 |
| Duration (Y), mean (SEM) | 7.7 | ( | 0.7 | ) | 7.2 | ( | 0.7 | ) | 8.3 | ( | 0.6 | ) | 8.6 | ( | 0.6 | ) | 0.44 | |
| Onset age(Y) | 61.8 | ( | 1.3 | ) | 60.9 | ( | 1.4 | ) | 59.5 | ( | 1.5 | ) | 61.7 | ( | 1.2 | ) | 0.61 | |
| Initial symptoms | Tremor dominant Others | 25 35 | ( ( | 41.7% 58.3% | ) ) | 25 25 | ( ( | 50.0% 50.0% | ) ) | 22 28 | ( ( | 44.0% 56.0% | ) ) | 27 29 | ( ( | 48.2% 51.8% | ) ) | 0.81 |
| H-Y | 1, 2 | 32 | ( | 53.3% | ) | 30 | ( | 60.0% | ) | 22 | ( | 44.0% | ) | 16 | ( | 28.6% | ) | 0.007 |
| 3, 4 | 28 | ( | 46.7% | ) | 20 | ( | 40.0% | ) | 28 | ( | 56.0% | ) | 40 | ( | 71.4% | ) | ||
| UPDRS-3, mean (SEM) | 20.3 | ( | 1.6 | ) | 21.1 | ( | 1.6 | ) | 20.7 | ( | 1.6 | ) | 20.4 | ( | 1.0 | ) | 0.98 | |
| Orthopedic spinal lesions | Yes No | 12 48 | ( ( | 20.0% 80.0% | )) | 9 41 | ( ( | 18.0% 82.0% | ) ) | 8 42 | ( ( | 16.0% 84.0% | ) ) | 12 44 | ( ( | 21.4% 78.6% | ) ) | 0.90 |
| History of psychosis | Yes No | 18 42 | ( ( | 30.0% 70.0% | ) ) | 10 40 | ( ( | 20.0% 80.0% | ) ) | 14 36 | ( ( | 28.0% 72.0% | ) ) | 19 37 | ( ( | 33.9% 66.1% | ) ) | 0.45 |
| Agonist-related history | Yes No | 9 51 | ( ( | 15.0% 85.0% | ) ) | 2 48 | ( ( | 4.0% 96.0% | ) ) | 2 48 | ( ( | 4.0% 96.0% | ) ) | 9 47 | ( ( | 16.1% 83.9% | ) ) | 0.0498 |
| Dopa, mean (SEM) | mg/day | 384 | ( | 27.1 | ) | 375 | ( | 27 | ) | 402 | ( | 27 | ) | 411 | ( | 22 | ) | 0.75 |
| Agonist LDED, mean (SEM) | mg/day | 104 | ( | 20 | ) | 105 | ( | 18 | ) | 111 | ( | 21 | ) | 96 | ( | 15 | ) | 0.95 |
| Dopa + Agonist, mean (SEM) | mg/day | 488 | ( | 32 | ) | 480 | ( | 31 | ) | 512 | ( | 35 | ) | 506 | ( | 26 | ) | 0.87 |
| Selegiline Use | Use No use | 23 37 | ( ( | 38.3% 61.7% | ) ) | 23 27 | ( ( | 46.0% 54.0% | ) ) | 20 30 | ( ( | 40.0% 60.0% | ) ) | 29 27 | ( ( | 51.8% 48.2% | ) ) | 0.46 |
| Amantadine Use | Use No use | 19 41 | ( ( | 31.7% 68.3% | ) ) | 7 43 | ( ( | 14.0% 86.0% | ) ) | 12 38 | ( ( | 24.0% 76.0% | ) ) | 15 41 | ( ( | 26.8% 73.2% | ) ) | 0.19 |
| Rehabilitation | Yes No | 9 51 | ( ( | 15.0% 85.0% | ) ) | 6 44 | ( ( | 12.0% 88.0% | ) ) | 8 42 | ( ( | 16.0% 84.0% | ) ) | 11 45 | ( ( | 19.6% 80.4% | ) ) | 0.75 |
p was calculated by ANOVA(scale variables) or by Pearson Chi square test (categorical variables).
Demographic data by quartiles of thoracolumbar angle.
| 1st quartile | 2nd quartile | 3rd quartile | 4th quartile | |||||||||||||||
| n = 56 | n = 51 | n = 52 | n = 57 | |||||||||||||||
| (0.2–3.9) | (4.0–7.1) | (7.4–11.2) | (11.5–54) |
| ||||||||||||||
| Age (Y), mean (SEM) | 66.7 | ( | 1.2 | ) | 66.6 | ( | 1.5 | ) | 71.1 | ( | 1.2 | ) | 71.4 | ( | 1.0 | ) | 0.003 | |
| Sex, n (%) | Female Male | 35 21 | ( ( | 62.5% 37.5% | ) ) | 30 21 | ( ( | 58.8% 41.2% | ) ) | 29 23 | ( ( | 55.8% 44.2% | ) ) | 39 18 | ( ( | 68.4% 31.6% | ) ) | 0.561 |
| Duration (Y), mean (SEM) | 6.9 | ( | 0.5 | ) | 7.1 | ( | 0.6 | ) | 8.2 | ( | 0.6 | ) | 9.5 | ( | 0.8 | ) | 0.021 | |
| Onset age(Y) | 59.8 | ( | 1.3 | ) | 59.5 | ( | 1.4 | ) | 62.9 | ( | 1.4 | ) | 61.9 | ( | 1.1 | ) | 0.21 | |
| Initial symptoms | Tremor dominant Others | 29 27 | ( ( | 51.8% 48.2% | ) ) | 24 27 | ( ( | 47.1% 52.9% | ) ) | 25 27 | ( ( | 48.1% 51.9% | ) ) | 21 36 | ( ( | 36.8% 63.2% | ) ) | 0.42 |
| H-Y | 1, 2 3, 4 | 32 24 | ( ( | 57.1% 42.9% | ) ) | 31 20 | ( ( | 60.8% 39.2% | ) ) | 23 29 | ( ( | 44.2% 55.8% | ) ) | 14 43 | ( ( | 24.6% 75.4% | ) ) | 0.0005 |
| UPDRS-3, mean (SEM) | 16.2 | ( | 1.2 | ) | 18.7 | ( | 1.4 | ) | 19.7 | ( | 1.1 | ) | 27.4 | ( | 1.7 | ) | <0.0001 | |
| Orthopedic spinal lesions | Yes No | 3 53 | ( ( | 5.4% 94.6% | ) ) | 7 44 | ( ( | 13.7% 86.3% | ) ) | 13 39 | ( ( | 25.0% 75.0% | ) ) | 18 39 | ( ( | 31.6% 68.4% | ) ) | 0.002 |
| History of psychosis | Yes No | 10 46 | ( ( | 17.9% 82.1% | ) ) | 11 40 | ( ( | 21.6% 78.4% | ) ) | 13 39 | ( ( | 25.0% 75.0% | ) ) | 27 30 | ( ( | 47.4% 52.6% | ) ) | 0.002 |
| Agonist-related history | Yes No | 2 54 | ( ( | 3.6% 96.4% | ) ) | 3 48 | ( ( | 5.9% 94.1% | ) ) | 9 43 | ( ( | 17.3% 82.7% | ) ) | 8 49 | ( ( | 14.0% 86.0% | ) ) | 0.06 |
| Dopa, mean (SEM) | mg/day | 340 | ( | 25 | ) | 337 | ( | 26 | ) | 456 | ( | 23 | ) | 437 | ( | 25 | ) | 0.0003 |
| Agonist LDED, mean (SEM) | mg/day | 115 | ( | 18 | ) | 136 | ( | 23 | ) | 120 | ( | 20 | ) | 49 | ( | 8 | ) | 0.003 |
| Dopa + Agonist, mean (SEM) | mg/day | 454 | ( | 32 | ) | 473 | ( | 37 | ) | 576 | ( | 28 | ) | 486 | ( | 25 | ) | 0.029 |
| Selegiline Use | Use No use | 23 33 | ( ( | 41.1% 58.9% | )) | 25 26 | ( ( | 49.0% 51.0% | ) ) | 25 27 | ( ( | 48.1% 51.9% | ) ) | 22 35 | ( ( | 38.6% 61.4% | ) ) | 0.63 |
| Amantadine Use | Use No use | 8 48 | ( ( | 14.3% 85.7% | ) ) | 11 40 | ( ( | 21.6% 78.4% | ) ) | 18 34 | ( ( | 34.6% 65.4% | ) ) | 16 41 | ( ( | 28.1% 71.9% | ) ) | 0.08 |
| Rehabilitation | Yes No | 8 48 | ( ( | 14.3% 85.7% | ) ) | 4 47 | ( ( | 7.8% 92.2% | ) ) | 8 44 | ( ( | 15.4% 84.6% | ) ) | 14 43 | ( ( | 24.6% 75.4% | ) ) | 0.12 |
p was calculated by ANOVA(scale variables) or by Pearson Chi square test (categorical variables).
Odds ratios of factors for quartiles of neck flexion angle.
| 2nd quartile | 3rd quartile | 4th quartile | ||||||||||||||||||||
| Predictable variables | OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| ||||||||||||||||
| Age | /Year | 0.88 | ( | 0.56 | – | 1.38 | ) | 0.57 | 0.77 | ( | 0.49 | – | 1.22 | ) | 0.27 | 0.97 | ( | 0.61 | – | 1.53 | ) | 0.89 |
| Sex | Male Female (Ref) | 2.01 1 | ( | 0.92 | – | 4.35 | ) | 0.08 | 1.08 1 | ( | 0.49 | – | 2.39 | ) | 0.85 | 1.07 1 | ( | 0.49 | – | 2.34 | ) | 0.87 |
| Orthopedic spinal lesions | Yes No (Ref) | 1.07 1 | ( | 0.38 | – | 2.98 | ) | 0.90 | 0.77 1 | ( | 0.27 | – | 2.18 | ) | 0.62 | 0.84 1 | ( | 0.32 | – | 2.20 | ) | 0.72 |
| Hoehn-Yahr | III, IV I, II (Ref) | 0.79 1 | ( | 0.35 | – | 1.78 | ) | 0.57 | 1.73 1 | ( | 0.78 | – | 3.88 | ) | 0.18 | 2.99 | ( | 1.33 | – | 6.7 | ) | 0.008 |
| 1 | ||||||||||||||||||||||
| The reference category is: 1st quartile. | ||||||||||||||||||||||
predictable variables: forced entry (age, sex, and orthopedic lesions), forward stepwise likelihood ratio test (duration of PD, H-Y, history of psychosis, history of agonist-related AP, UPDRS-3, Dopa dose, DA agonist dose, amantadine use, selegiline use, and rehabilitation).
Odds ratios of factors for quartiles of thoracolumbar angle.
| 2nd quartile | 3rd quartile | 4th quartile | ||||||||||||||||||||
| Predictable variables | OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| ||||||||||||||||
| Age | /Year | 0.94 | ( | 0.59 | – | 1.49 | ) | 0.79 | 1.58 | ( | 0.94 | – | 2.66 | ) | 0.08 | 1.01 | ( | 0.60 | – | 1.71 | ) | 0.96 |
| Sex | Female | 0.94 | ( | 0.41 | – | 2.18 | ) | 0.892 | 1.09 | ( | 0.46 | – | 2.57 | ) | 0.84 | 1.78 | ( | 0.72 | – | 4.40 | ) | 0.21 |
| Male (Ref) | 1 | 1 | 1 | |||||||||||||||||||
| Orthopedic spinal lesions | Yes | 3.41 | ( | 0.78 | – | 14.8 | ) | 0.102 | 3.58 | ( | 0.89 | – | 14.4 | ) | 0.073 | 5.83 | ( | 1.42 | – | 23.8 | ) | 0.014 |
| No (Ref) | 1 | 1 | 1 | |||||||||||||||||||
| UPDRS–3 | /10 points | 1.65 | ( | 0.99 | – | 2.77 | ) | 0.06 | 1.40 | ( | 0.84 | – | 2.34 | ) | 0.20 | 3.04 | ( | 1.80 | – | 5.15 | ) | <0.0001 |
| Dopa daily dose | /100mg | 0.91 | ( | 0.72 | – | 1.15 | ) | 0.44 | 1.33 | ( | 1.03 | – | 1.71 | ) | 0.03 | 1.07 | ( | 0.83 | – | 1.39 | ) | 0.59 |
| Agonist daily dose | /100mg LDED | 1.21 | ( | 0.90 | – | 1.63 | ) | 0.21 | 1.20 | ( | 0.88 | – | 1.63 | ) | 0.25 | 0.64 | ( | 0.39 | - | 1.07 | ) | 0.09 |
| The reference category is: 1st quartile. | ||||||||||||||||||||||
predictable variables: forced entry (age, sex, and orthopedic lesions), forward stepwise likelihood ratio test (duration of PD, H-Y, history of psychosis, history of agonist-related AP, UPDRS-3, Dopa dose, DA agonist dose, amantadine use, selegiline use, and rehabilitation).